Voyager Therapeutics (NASDAQ:VYGR) Rating Lowered to “Sell” at Wall Street Zen

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

VYGR has been the topic of a number of other reports. Wedbush restated an “outperform” rating and issued a $8.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, November 11th. HC Wainwright cut their target price on shares of Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Voyager Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $13.75.

Voyager Therapeutics Stock Up 2.0%

Shares of VYGR stock opened at $3.49 on Friday. Voyager Therapeutics has a twelve month low of $2.64 and a twelve month high of $5.55. The company has a market cap of $194.04 million, a P/E ratio of -1.62 and a beta of 1.30. The business has a fifty day simple moving average of $3.89 and a 200 day simple moving average of $4.09.

Insider Activity at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 12,192 shares of the stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $3.78, for a total value of $46,085.76. Following the completion of the sale, the chief executive officer owned 509,989 shares of the company’s stock, valued at approximately $1,927,758.42. This represents a 2.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders sold 20,286 shares of company stock valued at $77,248. Insiders own 6.39% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Several institutional investors have recently added to or reduced their stakes in VYGR. Invesco Ltd. increased its position in Voyager Therapeutics by 28.2% during the 4th quarter. Invesco Ltd. now owns 116,000 shares of the company’s stock valued at $456,000 after purchasing an additional 25,522 shares during the period. Sphera Funds Management LTD. boosted its stake in shares of Voyager Therapeutics by 70.1% in the 4th quarter. Sphera Funds Management LTD. now owns 339,761 shares of the company’s stock valued at $1,335,000 after purchasing an additional 140,000 shares during the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Voyager Therapeutics during the fourth quarter worth $120,000. Opaleye Management Inc. bought a new position in Voyager Therapeutics during the fourth quarter worth $4,704,000. Finally, EcoR1 Capital LLC raised its stake in Voyager Therapeutics by 497.2% during the fourth quarter. EcoR1 Capital LLC now owns 4,002,847 shares of the company’s stock worth $15,731,000 after buying an additional 3,332,544 shares during the last quarter. 48.03% of the stock is currently owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.